Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Visine** is a non-specific over-the-counter ophthalmic product brand rather than one defined drug substance. The brand includes redness-relief, allergy-relief, lubricating dry-eye, and multi-symptom eye-drop formulations with different active-ingredient compositions. For example, the classic redness-relief formulation contains tetrahydrozoline hydrochloride, an imidazoline sympathomimetic that constricts superficial conjunctival blood vessels; other Visine products are lubricant formulations or contain additional allergy-relief agents. The provided 2016 study evaluated a specific prototype lubricant formulation containing glycerin, hypromellose, polyethylene glycol 400, and polyquaternium-42 preservative, not every product marketed under the Visine name. Visine is currently a Kenvue consumer-health brand. ([visine.com](https://www.visine.com/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Visine.